Stately Bio: $12 Million Closed For Developing Regenerative Medicines With Cellular Imaging Platform
Stately Bio, a company developing cell therapies using an ML-based live-cell imaging platform, announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, ...
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results